



SOLARA
Active Pharma Sciences

Communication Address :
Solara Active Pharma Sciences Limited
Batra Centre
No. 28, Sardar Patel Road, Post Box 2630
Guindy, Chennai - 600 032, India
Tel : +91 44 43446700, 22207500
Fax : +91 44 22350278

January 28, 2019

The BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 541540

Scrip Code: SOLARA

Dear Sir / Madam,

Sub:- Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

We are enclosing herewith a press release issued by the Company titled:

“Solara completes yet another USFDA Inspection with zero 483s”

Thanking you,

Yours faithfully,
For Solara Active Pharma Sciences Limited


S. Murali Krishna
Company Secretary



Encl:- as above

Solara completes yet another USFDA Inspection with zero 483s

- **2nd Successive inspection with similar outcomes in last two months**
- **Reinforces Solara's commitment to the highest level of compliance**

Bangalore, India – January 28, 2019: Solara Active Pharma Science Limited (Solara), a leading Active Pharmaceutical Ingredient provider today announced the successful completion of US FDA inspection at its manufacturing facility in Ambernath, Maharashtra with zero 483s inspectional observations.

Solara's facility in Ambernath, Maharashtra is a multi-purpose API and intermediate facility. The facility can manufacture a wide range of complex APIs and advanced intermediates. It is equipped with clean rooms with a variety of isolation, drying, milling, and packaging equipment. This facility is also approved with EDQM.

Solara stays committed to demonstrating the highest level of compliance with yet another USFDA audit with "Zero 483s". In Dec'18, the company also completed US FDA inspection at Solara Research Centre(SRC), Chennai with zero 483s.

About Solara

Solara Active Pharma Sciences Ltd (BSE-541540, NSE-SOLARA) headquartered in Bengaluru, India offers a basket of diversified, high-value Commercial APIs and Contract manufacturing services in over 75 countries. It has a manufacturing base comprising five API facilities in India with approvals including the USFDA, EU GMP, KFDA and PMDA in Japan.

Investor / Analyst contact

Dikshita Jain

Christensen Investor Relations

✉ djain@christensenir.com

☎ +91 22 4215 0210

Statutory contact

Murali Krishna S

Raghavan. V

✉ investors@solara.co.in

☎ +91 44 4344 6700

Disclaimer: Certain statements in this document that are not historical facts are forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Solara Active Pharma Sciences Ltd will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.